西那卡塞对血液透析患者继发性甲状旁腺功能亢进的疗效观察  

Observation on efficacy of sinacaser on secondary hyperparathyroidism in hemodialysis patients

作　　者：陈展茂 吴武忠[1] 蔡瑜彬[1] CHEN Zhan-mao;WU Wu-zhong;CAI Yu-bin(Blood Purification Center of Jieyang People's Hospital, Jieyang 522000, China)

机构地区：[1]揭阳市人民医院血液净化中心,522000

出　　处：《中国实用医药》2019年第11期67-68,共2页China Practical Medicine

摘　　要：目的探索西那卡塞治疗血液透析患者继发性甲状旁腺功能亢进的效果。方法 50例血液透析继发性甲状旁腺功能亢进患者,根据随机数字表法分为观察组与对照组,各25例。对照组给予骨化三醇治疗,观察组在对照组治疗基础上给予西那卡塞治疗。比较两组治疗效果及治疗前后血清钙、血清磷、全段甲状旁腺激素(iPTH)水平的差异。结果观察组患者治疗总有效率为100.0%,明显高于对照组的84.0%,差异具有统计学意义(P<0.05)。治疗前,两组患者血清钙、血清磷、iPTH水平比较差异无统计学意义(P>0.05);治疗后,两组血清钙水平均明显升高,血清磷、iPTH水平明显降低,差异具有统计学意义(P<0.05);治疗后,观察组患者血清钙水平明显高于对照组,血清磷和iPTH水平明显低于对照组,差异均具有统计学意义(P<0.05)。结论西那卡塞在血液透析后继发性甲状旁腺功能亢进治疗中疗效显著,可改善患者甲状旁腺激素(PTH)分泌,值得推广。Objective To investigate the effect of sinacaser on secondary hyperparathyroidism in hemodialysis patients. Methods A total of 50 hemodialysis patients with secondary hyperparathyroidism were divided into observation group and control group according to random number table method, with 25 cases in each group. The control group was treated with calcitriol, and the observation group was treated with sinacaser on the basis of the control group. Comparison were made on treatment effect, differences of serum calcium, phosphorus and immunoreactive parathyroid hormone (iPTH) levels before and after treatment in two groups. Results The observation group had obviously higher total treatment effective rate as 100.0% than 84.0% in the control group, and the difference was statistically significant (P<0.05). Before treatment, both groups had no statistically significant difference in serum calcium, serum phosphorus and iPTH level (P>0.05). After treatment, both groups had obviously higher serum calcium, and obviously lower serum phosphorus and iPTH level. Their difference was statistically significant (P<0.05). After treatment, the observation group had obviously higher serum calcium level than the control group, and obviously lower serum phosphorus and iPTH level than the control group. Their difference was statistically significant (P<0.05). Conclusion Sinacaser shows significant efficacy in the treatment of secondary hyperparathyroidism after hemodialysis., and it can improve the secretion of parathyroid hormone (PTH). It is worth popularizing.

关 键 词：西那卡塞 骨化三醇 血液透析 继发性甲状旁腺功能亢进 

分 类 号：R692.5[医药卫生—泌尿科学]